|Videos|April 15, 2022
Future Directions in Prostate Cancer and Clinical Pearls for Clinicians
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5